<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Diagnosis of monoclonal gammopathy of undetermined significance</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Diagnosis of monoclonal gammopathy of undetermined significance</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Diagnosis of monoclonal gammopathy of undetermined significance</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jacob P Laubach, MD, MPP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">S Vincent Rajkumar, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rebecca F Connor, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 22, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Monoclonal gammopathy of undetermined significance (MGUS) is a clinically asymptomatic premalignant clonal plasma cell or lymphoplasmacytic proliferative disorder. It is defined by the presence of a serum monoclonal protein (M protein) at a concentration &lt;3 g/dL, a bone marrow with &lt;10 percent monoclonal plasma cells, and absence of end-organ damage (lytic bone lesions, anemia, hypercalcemia, kidney impairment, hyperviscosity) related to the proliferative process.</p><p>MGUS occurs in over 3 percent of the White population over the age of 50 and is typically detected as an incidental finding when individuals undergo a protein electrophoresis as part of an evaluation for a wide variety of clinical symptoms and disorders (eg, peripheral neuropathy, vasculitis, hemolytic anemia, skin rashes, hypercalcemia, or elevated erythrocyte sedimentation rate).</p><p>There are three distinct clinical types of MGUS, each with a risk of progressing through a unique intermediate (more advanced) premalignant stage and then to a malignant plasma cell dyscrasia or lymphoproliferative disorder [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Non-IgM MGUS (IgG, IgA, or IgD MGUS) – Non-IgM MGUS is the most common subtype of MGUS and has the potential to progress to smoldering (asymptomatic) multiple myeloma and to symptomatic multiple myeloma. Less frequently, these individuals progress to AL amyloidosis, light chain deposition disease, or another lymphoproliferative disorder.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>IgM MGUS – IgM MGUS accounts for approximately 15 percent of MGUS cases. It is considered separately from the non-IgM MGUS because it has the potential to progress to smoldering Waldenström macroglobulinemia and to symptomatic Waldenström macroglobulinemia, and less often to lymphoma or AL amyloidosis. Infrequently, IgM MGUS can progress to IgM multiple myeloma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Light chain MGUS (LC-MGUS) – LC-MGUS is a unique subtype of MGUS in which the secreted M protein lacks the immunoglobulin heavy chain component. LC-MGUS may progress to light chain smoldering multiple myeloma (idiopathic Bence Jones proteinuria) and to light chain multiple myeloma, AL amyloidosis, or light chain deposition disease [<a href="#rid2">2</a>].</p><p></p><p>The diagnosis of individuals with MGUS will be discussed here [<a href="#rid3">3-6</a>]. The management of individuals with MGUS, the recognition of serum or urinary M proteins, and a discussion of the clinical features, laboratory manifestations, and diagnosis of multiple myeloma and other plasma cell dyscrasias are presented separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15772.html" rel="external">"Clinical course and management of monoclonal gammopathy of undetermined significance"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6655.html" rel="external">"Laboratory methods for analyzing monoclonal proteins"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6657.html" rel="external">"Epidemiology, pathogenesis, clinical manifestations, and diagnosis of Waldenström macroglobulinemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6665.html" rel="external">"Monoclonal immunoglobulin deposition disease"</a>.)</p><p></p><p class="headingAnchor" id="H9"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>MGUS was found in approximately 1 to 2 percent of adults in studies from Sweden, the United States, France, and Japan [<a href="#rid7">7-11</a>]. The mean age at diagnosis is 70 years, and less than 2 percent of individuals are diagnosed before the age of 40 [<a href="#rid12">12,13</a>]. The incidence and prevalence rises with individual age [<a href="#rid12">12,14,15</a>], is higher in men than women [<a href="#rid12">12</a>], and is two- to threefold higher in Africans and African Americans compared with White Americans [<a href="#rid16">16-19</a>].</p><p>The incidence of MGUS in men is estimated to be 120 per 100,000 at age 50 and increases to 530 per 100,000 by the age of 90. The corresponding rates for women are 60 per 100,000 population at age 50, and 370 per 100,000 at age 90 [<a href="#rid15">15</a>].</p><p>The best estimates of prevalence come from population-based studies of a geographically defined area during a specific time period. Factors that influence the findings of such studies include demographic features of the screened population (ie, age, sex, race), the presence of risk factors for MGUS in the population (eg, occupational and environmental risk factors, immune status, and familial risk), and logistical features of the study (eg, how the study identified populations to screen, the sensitivity of the diagnostic tests used, and the diagnostic criteria used) [<a href="#rid20">20</a>]. Higher sensitivity techniques, such as mass spectrometry, are able to detect MGUS in an even greater percentage of the population [<a href="#rid21">21,22</a>].</p><p>The prevalence of MGUS among a well-defined, largely White population was determined by agarose gel electrophoresis followed by immunofixation in 21,463 of the 28,038 enumerated residents (77 percent) of Olmsted County, Minnesota, who were ≥50 years of age [<a href="#rid12">12</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The prevalence of MGUS in individuals ≥50, ≥70, and ≥85 years of age was 3.2, 5.3, and 7.5 percent, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Age-adjusted rates for individuals ≥50 were significantly higher in men than in women (4.0 versus 2.7 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Further evaluation noted the prevalence of light chain-MGUS and MGUS in individuals over age 50 was 0.8 and 3.4 percent, respectively [<a href="#rid23">23</a>].</p><p></p><p>Many studies have demonstrated the effects of race on MGUS frequency. A study from Ghana used stratified random sampling to estimate the incidence of MGUS in Black men from western Africa at twice that of the White population from Minnesota [<a href="#rid19">19</a>]. A two- to threefold higher frequency in MGUS among Black Americans was also seen in a large study of inpatients from United States Veterans Affairs hospitals [<a href="#rid18">18</a>] and a large population-based study of American women [<a href="#rid24">24</a>]. The latter study also showed that the increased risk of MGUS seen in Black Americans persists in a cohort of women of similar socioeconomic status. These and other studies suggest that the racial predisposition to MGUS and multiple myeloma observed in Black individuals is likely related to shared genetics, rather than environmental factors [<a href="#rid19">19,24</a>].</p><p>There is a paucity of information regarding the incidence in other populations. A study from Japan that used an older method for screening suggests that Japanese adults may have a slightly lower incidence than that seen in White Americans from Minnesota [<a href="#rid11">11</a>]. The limited data available also suggest that the prevalence of MGUS in Mexicans is less than in White Minnesotans [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H10"><span class="h2">Genetic predisposition</span><span class="headingEndMark"> — </span>While most cases of MGUS appear to be sporadic, relatives of individuals with MGUS or other plasma cell disorders have an increased risk of developing MGUS and related diseases [<a href="#rid26">26-30</a>]. Studies of the incidence of plasma cell and lymphoproliferative disorders among first-degree relatives of patients with multiple myeloma or MGUS support a shared environmental and/or genetic predisposition to these disorders.</p><p class="bulletIndent1"><span class="glyph">●</span>Using population-based data from Sweden, relatives of MGUS individuals had significantly increased risks for MGUS (relative risk [RR] 2.8), multiple myeloma (RR 2.9), lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (RR 4.0), and chronic lymphocytic leukemia (RR 2.0) [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Using a cohort of MGUS individuals from Olmsted County identified through a population-based prevalence study and individuals with myeloma or MGUS from the Mayo Clinic, the risk of MGUS was found to be significantly increased among relatives of those with myeloma (RR 2.0) or MGUS (RR 3.3) [<a href="#rid28">28,29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Further support for a genetic predisposition comes from genome-wide association studies and case-control studies that have demonstrated an association between certain relatively common normally occurring variants in genes, called single-nucleotide polymorphisms (SNPs), and an increased incidence of MGUS and myeloma [<a href="#rid31">31-33</a>].</p><p></p><p>Since there are no proven preventative approaches, there is no role for screening asymptomatic relatives at this time.</p><p class="headingAnchor" id="H90176672"><span class="h2">Associated conditions</span><span class="headingEndMark"> — </span>MGUS has been reported in association with several non-malignant disorders, some of them quite rare  (<a class="graphic graphic_table graphicRef70820" href="/z/d/graphic/70820.html" rel="external">table 1</a>) [<a href="#rid34">34</a>], and also has been reported along with autoimmune disorders such as systemic lupus erythematosus and immune thrombocytopenia (ITP) [<a href="#rid35">35,36</a>]. It is not clear whether these conditions are pathogenetically related or merely represent coincidental associations, given the relatively frequent occurrence of MGUS in the general population above the age of 50.</p><p>A population-based study of 17,398 subjects from Olmsted County found a number of previously unreported disease associations with MGUS, including mycobacterial infection and superficial thrombophlebitis [<a href="#rid37">37</a>]. An appendix providing the incidence of each of the 16,062 disease codes in individuals with MGUS and controls, along with relative risks and confidence intervals, is available as <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2719521%2Fbin%2Fsupp_84_8_685__index.html&amp;token=CtKwgY6uGORDzWPiZA0Ku80DLB0dA4KZli6YlAn5o7L9w1INTYY98ddT9qYe7kRHcR5tNj5FG1Q8Cii4sZjsasYNSiwbSizqYoEwSqCciQirWjELh4DBsVZzMMu5U5qn&amp;TOPIC_ID=6652" target="_blank">supplementary online content</a>. There is also an increased risk of fractures in individuals with MGUS compared with the general population [<a href="#rid38">38</a>].</p><p>Rare cases of telangiectasias, erythrocytosis with elevated erythropoietin, MGUS, perinephric fluid collections, and intrapulmonary shunting (TEMPI syndrome) have been reported in the literature, although little is known about the physiological basis of this constellation of symptoms [<a href="#rid39">39-42</a>]. Responses have been reported after administration of therapies used for plasma cell dyscrasias (eg, <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>, melphalan-based autologous hematopoietic cell transplantation, and <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">daratumumab</a>), suggesting that these symptoms are at least partially related to the underlying plasma cell dyscrasia [<a href="#rid41">41,43-46</a>].</p><p>Of importance, MGUS has been described in approximately one-third of individuals with acquired angioedema (acquired C1 inhibitor deficiency). Laryngeal edema is the most severe and potentially lethal complication of acquired angioedema, which may require urgent treatment with C1 inhibitor concentrate. (See  <a class="medical medical_review" href="/z/d/html/8112.html" rel="external">"Acquired C1 inhibitor deficiency: Clinical manifestations, epidemiology, pathogenesis, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/8110.html" rel="external">"Acquired C1 inhibitor deficiency: Management and prognosis"</a>.)</p><p class="headingAnchor" id="H90177415"><span class="h1">PRESENTING FEATURES</span><span class="headingEndMark"> — </span>By definition, individuals with MGUS have no symptoms of myeloma or related malignancy that can be attributable to their monoclonal (M) protein. Most individuals are identified when an M protein is detected as an incidental finding on protein electrophoresis performed as part of an evaluation for one of a wide variety of clinical symptoms and disorders (eg, peripheral neuropathy, vasculitis, hemolytic anemia, skin rashes, hypercalcemia, elevated erythrocyte sedimentation rate).</p><p>Since MGUS is asymptomatic, the condition is likely to have existed in an undetected state for years prior to diagnosis. As an example, a population-based prevalence study of 21,463 individuals from Olmsted County, Minnesota, estimated that more than half of individuals diagnosed with MGUS at age 70 had had an M protein for at least 10 years, and that approximately one-quarter had had an M protein for 20 years [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H90177423"><span class="h2">Monoclonal proteins</span><span class="headingEndMark"> — </span>MGUS (non-IgM and IgM) is characterized by the presence of an M protein produced and secreted by clonal plasma cells, which can be detected by protein electrophoresis of the serum (SPEP) and/or of an aliquot of urine (UPEP) from a 24-hour collection combined with immunofixation of the serum and urine  (<a class="graphic graphic_algorithm graphicRef94388" href="/z/d/graphic/94388.html" rel="external">algorithm 1</a>). Serum free light chain assays can detect low concentrations of monoclonal free light chain in the serum. They can be used to diagnose light-chain MGUS and predict the risk of progression of MGUS. While not widely available, mass spectrometry is used at some centers to identify and classify M proteins in the serum. (See  <a class="medical medical_review" href="/z/d/html/6655.html" rel="external">"Laboratory methods for analyzing monoclonal proteins", section on 'Indications and uses'</a>.)</p><p>The M protein usually presents as a single narrow peak, like a church spire, in the gamma, beta, or alpha-2 region of the densitometer tracing  (<a class="graphic graphic_figure graphicRef67685" href="/z/d/graphic/67685.html" rel="external">figure 1</a>) or as a dense, discrete band on the agarose gel  (<a class="graphic graphic_diagnosticimage graphicRef62500" href="/z/d/graphic/62500.html" rel="external">image 1</a>). Two M proteins are present (biclonal gammopathy) in 2 to 4 percent  (<a class="graphic graphic_figure graphicRef54186" href="/z/d/graphic/54186.html" rel="external">figure 2</a>) of individuals with clonal plasma cell disorders. (See  <a class="medical medical_review" href="/z/d/html/6655.html" rel="external">"Laboratory methods for analyzing monoclonal proteins"</a>.)</p><p>Serum immunofixation confirms the presence of an M protein and determines its type  (<a class="graphic graphic_figure graphicRef55916" href="/z/d/graphic/55916.html" rel="external">figure 3</a>). The clonal plasma cells can produce immunoglobulin heavy chains plus light chains or light chains alone, with the following approximate frequencies  (<a class="graphic graphic_table graphicRef73099" href="/z/d/graphic/73099.html" rel="external">table 2</a>) [<a href="#rid12">12,23,46,47</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>IgG – 55 percent</p><p class="bulletIndent1"><span class="glyph">●</span>IgM – 14 percent</p><p class="bulletIndent1"><span class="glyph">●</span>IgA – 9 percent</p><p class="bulletIndent1"><span class="glyph">●</span>IgD – &lt;1 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Biclonal – 3 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Kappa or lambda light chain only (no heavy chain) – 19 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Kappa light chain – 62 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Lambda light chain – 38 percent</p><p></p><p>The presence of an IgD M protein almost always indicates multiple myeloma, AL amyloid, or plasma cell leukemia, although two cases of IgD MGUS have been reported [<a href="#rid3">3</a>]. IgD M protein is difficult to detect at low concentrations and may evade detection. Of the approximately 0.8 percent of the population age ≥50 that have light chain-MGUS, 74 percent have a kappa light chain predominance [<a href="#rid23">23</a>].</p><p>The amount of M protein in MGUS is usually small and by definition less than 3 g/dL (30 g/L) in the serum. In a large population-based study, the concentration of monoclonal immunoglobulin was &lt;1.0 g/dL (10 g/L) in 63.5 percent and ≥2.0 g/dL (20 g/L) in 4.5 percent [<a href="#rid12">12</a>]. Approximately one-third of individuals will have a decrease in the concentration of uninvolved immunoglobulins (eg, IgM and IgA in the case of IgG MGUS) [<a href="#rid48">48,49</a>]. A monoclonal urinary light chain is seen in approximately 20 percent.</p><p class="headingAnchor" id="H90179087"><span class="h2">Biclonal gammopathy</span><span class="headingEndMark"> — </span>As noted above, 3 percent of individuals with MGUS had biclonal, rather than monoclonal, gammopathy. Such individuals have the same clinical spectrum as those with monoclonal gammopathy, and should be followed in the same manner [<a href="#rid50">50</a>]. (See  <a class="medical medical_review" href="/z/d/html/6655.html" rel="external">"Laboratory methods for analyzing monoclonal proteins", section on 'Biclonal gammopathy'</a>.)</p><p class="headingAnchor" id="H90177451"><span class="h2">Laboratory artifacts</span><span class="headingEndMark"> — </span>Circulating M proteins may interfere with one or more laboratory tests performed on liquid-based automated analyzers, either by precipitating during the analysis, or by virtue of their specific binding properties. The most common artifacts are a low value for HDL cholesterol, a high value for bilirubin, as well as altered measurement of inorganic phosphate. (See  <a class="medical medical_review" href="/z/d/html/6655.html" rel="external">"Laboratory methods for analyzing monoclonal proteins", section on 'Interference with laboratory tests'</a>.)</p><p>Although not a laboratory artifact, M protein can increase the serum viscosity and erythrocyte sedimentation rate (ESR).</p><p class="headingAnchor" id="H90177465"><span class="h2">Peripheral smear</span><span class="headingEndMark"> — </span>The complete blood count and peripheral smear are usually normal. Infrequently, rouleaux formation is seen. Rouleaux formation is the phenomenon in which red cells take on the appearance of a stack of coins in diluted suspensions of blood, and is seen in individuals with elevated serum protein levels  (<a class="graphic graphic_picture graphicRef74369" href="/z/d/graphic/74369.html" rel="external">picture 1</a>). The presence of circulating plasma cells of the same isotype in the peripheral blood, as detected using a slide-based immunofluorescence assay or flow cytometry, is more commonly seen with active MM, but can also be seen in some individuals with MGUS [<a href="#rid51">51,52</a>]. (See  <a class="medical medical_review" href="/z/d/html/4435.html" rel="external">"Evaluation of the peripheral blood smear", section on 'Initial approach'</a>.)</p><p class="headingAnchor" id="H90177472"><span class="h2">Bone marrow examination</span><span class="headingEndMark"> — </span>A bone marrow aspirate and biopsy must demonstrate fewer than 10 percent clonal plasma cells, or in the case of IgM MGUS, fewer than 10 percent infiltration by clonal lymphoplasmacytic cells. (See  <a class="medical medical_review" href="/z/d/html/4768.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of lymphoplasmacytic lymphoma", section on 'Bone marrow'</a>.)</p><p>Conventional cytogenetics are normal in individuals with MGUS because of the low proliferative rate and small number of plasma cells within the bone marrow samples. However, studies using more sensitive methods have shown that chromosomal abnormalities are very common in MGUS [<a href="#rid53">53</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Results obtained by interphase fluorescence in situ hybridization (FISH) demonstrate chromosomal aneuploidy (especially hyperdiploidy) in approximately 50 percent of individuals with MGUS [<a href="#rid54">54-56</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Translocations affecting the immunoglobulin heavy chain (IgH) locus on chromosome 14q32 and five key partner chromosomes have been observed in the remaining 50 percent of individuals with MGUS. These include: t(11;14) affecting the cyclin D1 gene, t(4;14) affecting the FGFR-3 and MMSET genes, t(6;14) affecting the cyclin D3 gene, t(14;16) affecting the cmaf gene, and t(14;20) affecting the mafB gene [<a href="#rid57">57,58</a>]. These five translocations are termed "primary" IgH translocations. (See  <a class="medical medical_review" href="/z/d/html/6660.html" rel="external">"Multiple myeloma: Pathobiology", section on 'Immunoglobulin heavy chain translocations'</a>.)</p><p></p><p>Chromosomal abnormalities detected by FISH, including hyperdiploidy, IgH translocations, and deletion of chromosome 13 are not used to differentiate MGUS from multiple myeloma. The specific abnormalities that might indicate a high rate of progression from MGUS to multiple myeloma have not yet been reliably identified [<a href="#rid53">53,55,59</a>].</p><p class="headingAnchor" id="H13"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H282159971"><span class="h2">Screening</span><span class="headingEndMark"> — </span>Universal screening of asymptomatic individuals of any age for monoclonal gammopathy is not recommended [<a href="#rid60">60</a>]. Such screening would be associated with high costs for payers and undue emotional burden on individuals with a low risk of progressing to a symptomatic disorder. However, screening can be considered in individuals over the age of 50 with two or more affected first-degree relatives with multiple myeloma or related disorder [<a href="#rid61">61</a>]. (See  <a class="medical medical_review" href="/z/d/html/15772.html" rel="external">"Clinical course and management of monoclonal gammopathy of undetermined significance", section on 'Disease progression'</a>.)</p><p class="headingAnchor" id="H90175591"><span class="h2">Evaluation</span></p><p class="headingAnchor" id="H2815743159"><span class="h3">Initial testing for all</span><span class="headingEndMark"> — </span>The diagnosis of MGUS is usually incidental when a monoclonal (M) protein &lt;3 g/dL (30 g/L) is found as part of the evaluation of another disorder, such as unexplained age-inappropriate bone loss, unexplained proteinuria, an elevated total protein in the blood, or peripheral neuropathy without a defined etiology  (<a class="graphic graphic_algorithm graphicRef94388" href="/z/d/graphic/94388.html" rel="external">algorithm 1</a>) [<a href="#rid60">60</a>].</p><p>At a minimum, individuals suspected of having MGUS should be evaluated with the following studies:</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count</p><p class="bulletIndent1"><span class="glyph">●</span>Serum calcium and creatinine</p><p class="bulletIndent1"><span class="glyph">●</span>Serum protein electrophoresis and immunofixation</p><p class="bulletIndent1"><span class="glyph">●</span>Serum free light chain (FLC) assay</p><p class="bulletIndent1"><span class="glyph">●</span>Quantitative immunoglobulins</p><p></p><p>The serum FLC assay can be used initially in place of urine studies. However, if an M protein is seen on serum studies or if the serum FLC ratio is abnormal, urine studies need to be performed. </p><p>Urine studies usually include routine urinalysis and 24-hour urine collection with electrophoresis and immunofixation. Routine dipstick of the urine for protein is not sufficient. The dipstick primarily detects albumin, the excretion of which is typically increased in individuals with amyloidosis involving the kidney, but the dipstick test often does not detect immunoglobulin light chains. Alternatively, one could perform protein electrophoresis and immunofixation on a single voided urine specimen. A 24-hour collection to quantitate urinary protein excretion would be necessary only if the "spot test" result is positive. (See  <a class="medical medical_review" href="/z/d/html/3101.html" rel="external">"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults", section on 'Detection and measurement of total urinary protein excretion'</a> and  <a class="medical medical_patient" href="/z/d/html/2181.html" rel="external">"Patient education: Collection of a 24-hour urine specimen (Beyond the Basics)"</a>.)</p><p>While not widely available, mass spectrometry is being used for identification of M proteins at some centers. (See  <a class="medical medical_review" href="/z/d/html/6655.html" rel="external">"Laboratory methods for analyzing monoclonal proteins", section on 'Mass spectrometry'</a>.)<strong> </strong></p><p class="headingAnchor" id="H2308974088"><span class="h3">Cross sectional imaging</span><span class="headingEndMark"> — </span>Imaging is indicated for a subset of individuals to evaluate for multiple myeloma. We suggest whole body low dose computed tomography (CT) without contrast or whole-body magnetic resonance imaging (MRI) for most individuals with MGUS. These modalities are more sensitive than plain radiographs for the detection of most skeletal lesions in myeloma. Imaging in myeloma is discussed separately (See  <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'Imaging'</a>.)</p><p>Imaging may be omitted in individuals without anemia, hypercalcemia, and kidney impairment who have one of the following low-risk scenarios [<a href="#rid62">62-64</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>IgG monoclonal protein &lt;1.5 g/dL (15 g/L) and a normal serum FLC ratio</p><p class="bulletIndent1"><span class="glyph">●</span>Light chain only monoclonal protein with serum FLC ratio &lt;8</p><p class="bulletIndent1"><span class="glyph">●</span>IgM monoclonal protein with no clinical concern for bone lesions or myeloma  </p><p></p><p>Such individuals have a low risk of multiple myeloma or Waldenstrom macroglobulinemia requiring therapy.</p><p class="headingAnchor" id="H4158085372"><span class="h3">Bone marrow aspiration and biopsy</span><span class="headingEndMark"> — </span>A bone marrow aspiration and biopsy is indicated in all individuals with evidence of a monoclonal protein and any of the following: </p><p class="bulletIndent1"><span class="glyph">●</span>Anemia (hemoglobin &lt;10 g/dL or 2 g/dL below normal)</p><p class="bulletIndent1"><span class="glyph">●</span>Kidney impairment (serum creatinine &gt;2 mg/dL [176.8 micromol/liter])</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated serum calcium (serum calcium &gt;11.5 mg/dL [2.875 mmol/liter])</p><p class="bulletIndent1"><span class="glyph">●</span>Abnormalities on imaging</p><p></p><p>It is also indicated for most individuals with an M protein ≥1.5 g/dL (15 g/L), individuals with IgA MGUS of any size, and most individuals with an abnormal serum FLC ratio.</p><p>Bone marrow evaluation can be deferred in individuals with no evidence of anemia, lymphadenopathy, or organomegaly with the following low-risk scenarios [<a href="#rid6">6,61,63</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>IgG or IgM monoclonal protein &lt;1.5 g/dL (15 g/L) with normal FLC ratio</p><p class="bulletIndent1"><span class="glyph">●</span>Light chain only monoclonal protein with FLC ratio &lt;8 </p><p></p><p>Bone marrow may also be deferred in older asymptomatic adults or in frail older adults with limited life expectancy in whom myeloma or a related malignancy is considered unlikely, who can be safely followed. </p><p>Omission of the bone marrow evaluation in individuals with IgG-type MGUS with serum M protein &lt;1.5 g/dL (15 g/L), a normal serum FLC ratio, and with no bone pain or clinical concern for myeloma is supported by a study of 1271 individuals with MGUS or multiple myeloma with minimal bone pain (grade 0/1) whose initial workup included bone marrow evaluation and skeletal survey (without serum FLC analysis) with the following results [<a href="#rid63">63</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Among individuals with an M protein ≤1.5 g/dL (15 g/L), the percentage of individuals with bone marrow plasma cell infiltration &gt;10 percent was 7.3 percent overall but ranged from 4.7 percent to 20 percent in those with IgG and IgA isotypes, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For those with an IgG M protein &lt;0.5 g/dL (5 g/L), &lt;1 percent had bone marrow plasma cell infiltration &gt;10 percent by morphology.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similarly, among those with an IgG M protein ≤1.5 g/dL (15 g/L), the percentage of individuals with bone lesions on skeletal survey was &lt;2 percent.</p><p></p><p>The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fistopmm.org%2Friskmodel%2F&amp;token=4at6JGNyw20mdU8q%2Fj%2B1KY890ge1uxmV73D4bZbhF20mfGSdKzGAHhPv4TIpSBI5&amp;TOPIC_ID=6652" target="_blank">iStopMM risk model</a> has been proposed as an alternative method of estimating the risk of bone marrow involvement. This model was developed using data from &gt;1000 persons included in the iStopMM prospective population-based screening study who underwent bone marrow aspiration and biopsy as part of a planned follow-up strategy [<a href="#rid65">65</a>]. It excluded participants who had features suggestive of multiple myeloma (eg, anemia, kidney impairment, hypercalcemia, or bone lesions). The model incorporates the following factors:</p><p class="bulletIndent1"><span class="glyph">●</span>MGUS isotype (IgG, IgA, biclonal)</p><p class="bulletIndent1"><span class="glyph">●</span>M-protein concentration</p><p class="bulletIndent1"><span class="glyph">●</span>FLC ratio</p><p class="bulletIndent1"><span class="glyph">●</span>Total concentrations of IgG, IgA, and IgM</p><p></p><p>In an initial report, this model had a 97 percent negative predictive value. If this model were used to defer bone marrow sampling for those estimated to have 5 percent bone marrow involvement, it would allow 36 percent of the population to defer bone marrow of whom the vast majority (356 of 366 participants) had &lt;10 percent bone marrow plasma cells upon biopsy. A comparison with the Mayo Clinic model in this population suggested that the iStopMM model would allow more participants to avoid unnecessary bone marrow sampling. We await full publication of this model before incorporating it into routine practice.</p><p>Further details on risk stratification of individuals with MGUS and expected clinical course are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/15772.html" rel="external">"Clinical course and management of monoclonal gammopathy of undetermined significance", section on 'Risk stratification to estimate risk of progression'</a>.)</p><p class="headingAnchor" id="H90176110"><span class="h2">Diagnostic criteria</span></p><p class="headingAnchor" id="H90176118"><span class="h3">Non-IgM MGUS</span><span class="headingEndMark"> — </span>Non-IgM MGUS (IgG, IgA, or IgD MGUS) is diagnosed by meeting the following three criteria  (<a class="graphic graphic_algorithm graphicRef94388" href="/z/d/graphic/94388.html" rel="external">algorithm 1</a>) [<a href="#rid1">1,66,67</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The presence of a serum M protein (whether IgA, IgG, or IgD), at a concentration &lt;3 g/dL (&lt;30 g/L). The M protein is detected with serum protein electrophoresis followed by immunofixation for the identification of the M protein type  (<a class="graphic graphic_figure graphicRef67685" href="/z/d/graphic/67685.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef55916" href="/z/d/graphic/55916.html" rel="external">figure 3</a>) [<a href="#rid68">68</a>]. It must be distinguished from a polyclonal gammopathy  (<a class="graphic graphic_figure graphicRef74708" href="/z/d/graphic/74708.html" rel="external">figure 4</a>). (See  <a class="medical medical_review" href="/z/d/html/6655.html" rel="external">"Laboratory methods for analyzing monoclonal proteins"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fewer than 10 percent clonal plasma cells in the bone marrow.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The absence of lytic bone lesions, anemia, hypercalcemia, and kidney impairment related to the plasma cell proliferative process. </p><p></p><p>Note that serum involved/uninvolved FLC ratio is almost always &lt;100, and if it is ≥100, care must be taken to fully evaluate, including bone marrow and imaging, to rule out myeloma. </p><p class="headingAnchor" id="H174976281"><span class="h3">IgM MGUS</span><span class="headingEndMark"> — </span>IgM MGUS is diagnosed by meeting the following three criteria  (<a class="graphic graphic_algorithm graphicRef94388" href="/z/d/graphic/94388.html" rel="external">algorithm 1</a>) [<a href="#rid1">1,66,67</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The presence of a serum IgM M protein at a concentration &lt;3 g/dL (&lt;30 g/L). The M protein is detected with serum protein electrophoresis followed by immunofixation for the identification of the M protein type  (<a class="graphic graphic_figure graphicRef67685" href="/z/d/graphic/67685.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef55916" href="/z/d/graphic/55916.html" rel="external">figure 3</a>) [<a href="#rid68">68</a>]. It must be distinguished from a polyclonal gammopathy  (<a class="graphic graphic_figure graphicRef74708" href="/z/d/graphic/74708.html" rel="external">figure 4</a>). (See  <a class="medical medical_review" href="/z/d/html/6655.html" rel="external">"Laboratory methods for analyzing monoclonal proteins"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fewer than 10 percent clonal lymphoplasmacytic/plasma cells in the bone marrow.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The absence of end-organ damage such as anemia, constitutional symptoms, hyperviscosity, lymphadenopathy, or hepatosplenomegaly related to the plasma cell proliferative process. These individuals must then be followed [<a href="#rid69">69</a>]. (See  <a class="medical medical_review" href="/z/d/html/6657.html" rel="external">"Epidemiology, pathogenesis, clinical manifestations, and diagnosis of Waldenström macroglobulinemia", section on 'Clinical presentation'</a>.)</p><p></p><p>Note that serum involved/uninvolved FLC ratio is almost always &lt;100, and if it is ≥100, care must be taken to fully evaluate, including bone marrow and imaging, to rule out myeloma.</p><p class="headingAnchor" id="H90176125"><span class="h3">Light chain MGUS</span><span class="headingEndMark"> — </span>Light chain MGUS (LC-MGUS) is diagnosed by meeting the following criteria  (<a class="graphic graphic_algorithm graphicRef94388" href="/z/d/graphic/94388.html" rel="external">algorithm 1</a>) [<a href="#rid1">1,23</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The presence of an abnormal FLC ratio.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased level of the appropriate involved light chain (eg, increased kappa FLC in individuals with a high ratio and increased lambda FLC in individuals with a low ratio).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>No monoclonal immunoglobulin heavy chain (IgG, IgA, IgD, or IgM).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fewer than 10 percent clonal plasma cells in the bone marrow.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The absence of lytic bone lesions, anemia, hypercalcemia, and kidney impairment related to the plasma cell proliferative process. </p><p></p><p>Note that serum involved/uninvolved FLC ratio is almost always &lt;100, and if it is ≥100, care must be taken to fully evaluate, including bone marrow and imaging, to rule out myeloma.</p><p>When interpreting the FLC assay in clinical practice, clinicians should refer to the normal reference range specified by the laboratory reporting the result. Reference ranges differ between assays from different manufacturers and are dependent upon the instrument used for measurement. (See  <a class="medical medical_review" href="/z/d/html/6655.html" rel="external">"Laboratory methods for analyzing monoclonal proteins", section on 'Serum free light chains'</a>.)</p><p>FLC concentration is affected by kidney function and the reference intervals used for the FLC ratio (and FLC level) should be adjusted for the estimated glomerular filtration rate (eGFR) [<a href="#rid70">70,71</a>]; for the serum FLC assay developed by The Binding Site:</p><p class="bulletIndent1"><span class="glyph">●</span>eGFR ≥60 mL/min/1.73 m<sup>2</sup> </p><p class="bulletIndent3"><span class="glyph">-</span>FLC ratio 0.26 to 1.65</p><p class="bulletIndent3"><span class="glyph">-</span>Serum free kappa 3.3 to 19.4 mg/L</p><p class="bulletIndent3"><span class="glyph">-</span>Serum free lambda 5.7 to 26.3 mg/L</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>eGFR 45 to 59 mL/min/1.73 m<sup>2</sup></p><p class="bulletIndent3"><span class="glyph">-</span>FLC ratio 0.46 to 2.62</p><p class="bulletIndent3"><span class="glyph">-</span>Serum free kappa 7.8 to 83.6 mg/L</p><p class="bulletIndent3"><span class="glyph">-</span>Serum free lambda 7.3 to 65.1 mg/L</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>eGFR 30 to 44 mL/min/1.73 m<sup>2</sup></p><p class="bulletIndent3"><span class="glyph">-</span>FLC ratio 0.48 to 3.38</p><p class="bulletIndent3"><span class="glyph">-</span>Serum free kappa 8.8 to 103.3 mg/L</p><p class="bulletIndent3"><span class="glyph">-</span>Serum free lambda 8.2 to 73.2 mg/L</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>eGFR &lt;30 mL/min/1.73 m<sup>2</sup></p><p class="bulletIndent3"><span class="glyph">-</span>FLC ratio 0.54 to 3.30</p><p class="bulletIndent3"><span class="glyph">-</span>Serum free kappa 11.7 to 265 mg/L</p><p class="bulletIndent3"><span class="glyph">-</span>Serum free lambda 12.6 to 150.9 mg/L</p><p></p><p>Subjects with an abnormal FLC ratio and no expression of an immunoglobulin heavy chain, but without an increased concentration of the involved light chain, are not considered to have LC-MGUS. Instead, abnormal FLC ratios in these individuals likely reflect kidney impairment or polyclonal activation. (See  <a class="medical medical_review" href="/z/d/html/6655.html" rel="external">"Laboratory methods for analyzing monoclonal proteins", section on 'Use in patients with kidney impairment'</a>.)</p><p class="headingAnchor" id="H14"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>It is important to distinguish MGUS from more advanced plasma cell dyscrasias for the purposes of prognosis and treatment. The main conditions to consider in the differential diagnosis of MGUS are multiple myeloma (smoldering or symptomatic), Waldenström macroglobulinemia (smoldering or symptomatic), idiopathic Bence Jones proteinuria, and primary amyloidosis (AL)  (<a class="graphic graphic_table graphicRef67431" href="/z/d/graphic/67431.html" rel="external">table 3</a>).</p><p class="headingAnchor" id="H15"><span class="h2">Multiple myeloma</span><span class="headingEndMark"> — </span>Both MGUS and multiple myeloma (MM) are characterized by a monoclonal (M) protein in the serum (IgG, IgA, or IgD; kappa or lambda) or in the urine (kappa or lambda) that is produced by a clonal population of plasma cells in the bone marrow. A subset of individuals with MGUS will progress to smoldering (asymptomatic) MM and then to symptomatic MM. It is impossible to differentiate MGUS from those who subsequently develop smoldering or symptomatic MM at the time of initial presentation.</p><p>By definition, any individual with a non-IgM serum M protein ≥3 g/dL (30 g/L), with a serum involved/uninvolved free light chain (FLC) ratio ≥100, or with ≥10 percent clonal plasma cells in the bone marrow does <strong>not</strong> have MGUS  (<a class="graphic graphic_table graphicRef130091" href="/z/d/graphic/130091.html" rel="external">table 4</a>). In such a case, a diagnosis of MM or smoldering MM (SMM) should be made. The morphologic appearance of the plasma cells in the bone marrow is of little help unless the cells have plasmablastic morphologic features (eg, nucleoli), which favors the diagnosis of MM [<a href="#rid72">72</a>]. However, due to patchy bone marrow involvement, approximately 4 percent of individuals with MM will have a bone marrow aspirate and biopsy demonstrating less than 10 percent clonal plasma cells [<a href="#rid73">73</a>].</p><p>While the diagnosis of MGUS requires the absence of anemia, hypercalcemia, kidney impairment, and lytic bone lesions related to the plasma cell proliferative disorder, the mere presence of one or more of these features in conjunction with an M protein does not automatically indicate MM or related malignancy, since these abnormalities may be due to unrelated coexisting diseases. As an example, individuals with MGUS may have anemia related to nutritional deficiency; kidney impairment related to coexisting diabetes or hypertension; hypercalcemia due to hyperparathyroidism; or lytic bone lesions from metastatic carcinoma. Only individuals in whom these clinical findings of end organ damage are felt to be clearly related to the plasma cell disorder are considered to have MM. (See  <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>The presence of osteolytic lesions and unexplained hypercalcemia strongly suggests MM, but metastatic carcinoma must be excluded.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similarly, unexplained kidney impairment suggests possible involvement by the light chains due to MGUS, MM, or a related malignancy. If kidney impairment is not accompanied by significant light chain excretion or other features of MM, a kidney biopsy may be needed to ascertain that the kidney impairment is caused by the plasma cell proliferative process [<a href="#rid74">74</a>]. (See  <a class="medical medical_review" href="/z/d/html/3067.html" rel="external">"The kidney biopsy"</a> and  <a class="medical medical_review" href="/z/d/html/109635.html" rel="external">"Diagnosis and treatment of monoclonal gammopathy of renal significance"</a>.)</p><p></p><p>Other laboratory determinations, such as a low CD4 cell count, chromosomal abnormalities with FISH analysis (eg, deletion 13), the presence of J chains in plasma cells, and elevated plasma cell acid phosphatase levels are all unreliable for differentiation of MGUS and MM. More sophisticated techniques of differentiating MGUS from MM (eg, plasma cell labeling index, serum concentration of interleukin [IL]-6, gene expression profiling) are not used in routine clinical practice [<a href="#rid51">51,52,75-79</a>]. However, a clearly elevated level of beta-2 microglobulin in the absence of kidney failure and/or an inflammatory process would suggest a diagnosis of MM, and the individual should be carefully evaluated for this possibility.</p><p>If there are doubts about the differentiation of MGUS and SMM from MM, and whether to begin chemotherapy immediately, one should withhold treatment and re-evaluate in two or three months. (See  <a class="medical medical_review" href="/z/d/html/6643.html" rel="external">"Multiple myeloma: Overview of management"</a>.)</p><p class="headingAnchor" id="H90179596"><span class="h3">Smoldering multiple myeloma</span><span class="headingEndMark"> — </span>Smoldering multiple myeloma (SMM), also called asymptomatic MM, is an intermediate stage between MGUS and symptomatic MM. SMM is diagnosed in individuals who meet the following criteria  (<a class="graphic graphic_table graphicRef57627" href="/z/d/graphic/57627.html" rel="external">table 5</a> and <a class="graphic graphic_table graphicRef130091" href="/z/d/graphic/130091.html" rel="external">table 4</a>) [<a href="#rid67">67,80,81</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Serum M protein ≥3 g/dL (30 g/L) and/or ≥10 to &lt;60 percent bone marrow clonal plasma cells.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Absence of lytic lesions, anemia, hypercalcemia, and kidney impairment (end-organ damage) attributable to the underlying plasma cell proliferation.</p><p></p><p>SMM is distinguished from MGUS based on the size of the M protein and the percent plasma cells in the bone marrow. (See  <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'Smoldering multiple myeloma'</a>.)</p><p>SMM is distinguished from MM based on the absence or presence of end-organ damage (hypercalcemia, anemia, bone lesions, kidney impairment) that is thought to be related to the underlying plasma cell disorder.</p><p>Individuals with SMM should have less than 60 percent bone marrow clonal plasma cells. Individuals who have 60 percent or more clonal bone marrow plasma cells rarely present without end-organ damage attributable to the plasma cell disorder, and even if they do present as such, they almost inevitably progress to overt MM within two years (median time to progression is seven months) [<a href="#rid82">82</a>]. Therefore, such individuals are best considered as having MM even in the absence of end-organ damage. Similarly, individuals with serum involved/uninvolved free light chain (FLC) ratio of 100 or more, and those with &gt;1 focal lesion on magnetic resonance imaging have a rate of progression within the first two years that is high enough to justify systemic therapy.</p><p class="headingAnchor" id="H3994119540"><span class="h3">Light chain smoldering multiple myeloma (Idiopathic Bence Jones proteinuria)</span><span class="headingEndMark"> — </span>Monoclonal light chains can be found in the urine (Bence Jones proteinuria) if their production exceeds the rate of light chain re-absorption in the kidneys  (<a class="graphic graphic_figure graphicRef55073" href="/z/d/graphic/55073.html" rel="external">figure 5</a> and <a class="graphic graphic_figure graphicRef75044" href="/z/d/graphic/75044.html" rel="external">figure 6</a>) [<a href="#rid83">83</a>]. FLCs are present in a subset of individuals with MM, AL amyloidosis, and WM; in MM and AL amyloidosis they may be present with or without an associated heavy chain component. Light chain smoldering multiple myeloma (LC-SMM) is an intermediate stage between light chain MGUS and light chain MM characterized by the presence of monoclonal FLCs without any detectable heavy chain component (eg, IgG, IgA, IgM) [<a href="#rid2">2</a>].</p><p>To make a diagnosis of LC-SMM, the following criteria must be met [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Monoclonal light chains in the urine (Bence Jones proteinuria) with a level ≥0.5 g/24 hours or associated with ≥10 to 60 percent bone marrow plasma cells, or both.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>No immunoglobulin heavy chain expression in the serum or urine.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>No lytic bone lesions, hypercalcemia, anemia, kidney impairment or other myeloma-defining events, WM, or AL amyloidosis.</p><p></p><p>Note that serum involved/uninvolved FLC ratio is almost always &lt;100, and if it is ≥100, care must be taken to fully evaluate, including bone marrow and imaging, to rule out myeloma. Elevation of serum involved FLC ratio ≥100 with bone marrow plasma cell involvement ≥10 percent indicates myeloma.</p><p class="headingAnchor" id="H62135187"><span class="h3">Secondary MGUS</span><span class="headingEndMark"> — </span>Secondary MGUS refers to the development of a new M protein during the course of MM that has an isotype (heavy and/or light chain) distinct from the original clone (eg, IgM MGUS in an individual with IgG MM). In a series of 1942 patients with MM, secondary MGUS developed in 128 (6.6 percent) at a median of 12 months from the diagnosis of myeloma [<a href="#rid84">84</a>]. More than one isotype occurred in approximately 30 percent of patients. Secondary MGUS was much more common among patients who had undergone hematopoietic cell transplantation and was associated with superior survival in this study. The additional M protein that occurs following transplantation commonly resolved without treatment with a median duration of approximately six months.</p><p class="headingAnchor" id="H90179678"><span class="h2">Waldenström macroglobulinemia</span><span class="headingEndMark"> — </span>Waldenström macroglobulinemia (WM) is a distinct clinicopathologic entity demonstrating lymphoplasmacytic lymphoma (LPL) in the bone marrow with an IgM monoclonal gammopathy in the blood. Unlike individuals with IgM MGUS who are asymptomatic, patients with WM may present with symptoms related to the infiltration of the hematopoietic tissues or the effects of monoclonal IgM in the blood. Symptoms of hyperviscosity and the presence of lymphadenopathy and/or splenomegaly favor a diagnosis of WM. There is a greater probability of an abnormal FLC ratio in WM compared with IgM MGUS. In one study, an abnormal kappa/lambda serum FLC ratio was found in 76 and 24 percent of those with WM and IgM MGUS, respectively [<a href="#rid85">85</a>]. Abnormalities in MYD88 can be seen in both WM and IgM MGUS [<a href="#rid86">86,87</a>]. Smoldering WM is considered an intermediate entity between IgM MGUS and WM, which fits the diagnostic criteria for WM but has not yet resulted in symptoms. (See  <a class="medical medical_review" href="/z/d/html/6657.html" rel="external">"Epidemiology, pathogenesis, clinical manifestations, and diagnosis of Waldenström macroglobulinemia"</a> and  <a class="medical medical_review" href="/z/d/html/4768.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of lymphoplasmacytic lymphoma"</a>.)</p><p>To make a diagnosis of WM (smoldering or symptomatic), the following criteria must be met [<a href="#rid88">88</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>An IgM monoclonal gammopathy (of any size) must be present in the serum.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ten percent or more of the bone marrow biopsy sample must demonstrate infiltration by LPL.</p><p></p><p>Individuals without end-organ damage such as anemia, constitutional symptoms, hyperviscosity, lymphadenopathy, or hepatosplenomegaly related to the lymphoplasmacytic cell proliferative process are considered to have smoldering WM and must be followed closely [<a href="#rid69">69</a>]. (See  <a class="medical medical_review" href="/z/d/html/6657.html" rel="external">"Epidemiology, pathogenesis, clinical manifestations, and diagnosis of Waldenström macroglobulinemia", section on 'Clinical presentation'</a>.)</p><p class="headingAnchor" id="H19"><span class="h2">AL amyloidosis and light chain deposition disease</span><span class="headingEndMark"> — </span>Primary (amyloid light chain) amyloidosis and light chain deposition disease are plasma cell or, less commonly, B cell proliferative disorders associated with the pathologic deposition of monoclonal light chains. In primary (AL) amyloidosis, there is deposition of linear non-branching fibrils that are derived from monoclonal immunoglobulin light chains. The deposition of these fibrils within organs can produce the nephrotic syndrome, heart failure, hepatomegaly, vascular fragility and abnormal coagulation times with associated excess bruising, and other findings that are not seen in MGUS. </p><p>In light chain deposition disease, there is deposition of intact monoclonal immunoglobulin light chains commonly in the kidney resulting in nephrotic syndrome. Like AL amyloidosis, light chain deposition disease can affect other organs including the heart and liver. (See  <a class="medical medical_review" href="/z/d/html/6665.html" rel="external">"Monoclonal immunoglobulin deposition disease"</a> and  <a class="medical medical_review" href="/z/d/html/6668.html" rel="external">"Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis"</a>.)</p><p>As noted above, the diagnosis of MGUS requires the absence of anemia, hypercalcemia, kidney impairment, and lytic bone lesions related to the plasma cell proliferative disorder. However, the presence of kidney impairment in conjunction with an M protein does not automatically indicate AL amyloidosis or other pathologic process related to the underlying dysproteinemia, since these abnormalities may be unrelated (eg, MGUS in an individual with kidney impairment secondary to diabetic or hypertensive nephropathy).</p><p>The diagnosis of primary AL amyloidosis is initially suspected from typical clinical findings (eg, macroglossia, neuropathy, periorbital purpura, nephrotic range proteinuria, restrictive cardiomyopathy, in conjunction with a serum or urinary M protein) and is confirmed by demonstrating the following two features:</p><p class="bulletIndent1"><span class="glyph">●</span>The presence of amyloid deposition on biopsy of the abdominal fat pad, bone marrow, rectum, or, if necessary, the involved organ (eg, kidney, liver, sural nerve), <strong>plus</strong>:</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evidence of a clonal plasma cell proliferative disorder, or less commonly a clonal B cell disorder.</p><p></p><p class="headingAnchor" id="H2276436808"><span class="h2">POEMS syndrome</span><span class="headingEndMark"> — </span>POEMS syndrome (<strong>P</strong>olyneuropathy, <strong>O</strong>rganomegaly, <strong>E</strong>ndocrinopathy, <strong>M</strong>onoclonal protein, <strong>S</strong>kin changes) is characterized by the presence of a monoclonal plasma cell disorder, peripheral neuropathy, and more than one of the following features: osteosclerotic myeloma, Castleman disease (angiofollicular lymph node hyperplasia), increased levels of serum vascular endothelial growth factor (VEGF), organomegaly, endocrinopathy, edema, typical skin changes, and papilledema. POEMS syndrome can be distinguished from MGUS using the diagnostic criteria shown in the table  (<a class="graphic graphic_table graphicRef64782" href="/z/d/graphic/64782.html" rel="external">table 6</a>). (See  <a class="medical medical_review" href="/z/d/html/6662.html" rel="external">"POEMS syndrome"</a>.)</p><p class="headingAnchor" id="H11684707"><span class="h1">CLINICAL COURSE AND MANAGEMENT</span><span class="headingEndMark"> — </span>Each of the three distinct clinical types of MGUS has a small risk of progressing to a unique intermediate (more advanced) premalignant stage and to a malignant plasma cell dyscrasia or lymphoproliferative disorder. Individuals with MGUS should be monitored for disease progression and for potential complications. This is presented in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/15772.html" rel="external">"Clinical course and management of monoclonal gammopathy of undetermined significance", section on 'Monitoring for progression'</a>.)</p><p class="headingAnchor" id="H978881612"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/119643.html" rel="external">"Society guideline links: Monoclonal gammopathy of undetermined significance"</a>.)</p><p class="headingAnchor" id="H363797431"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/86741.html" rel="external">"Patient education: Monoclonal gammopathy of undetermined significance (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H39"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and epidemiology</strong> – Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic premalignant clonal plasma cell or lymphoplasmacytic proliferative disorder. MGUS occurs in over 3 percent of the general White population over the age of 50 and is typically detected as an incidental finding when individuals undergo a protein electrophoresis as part of an evaluation for a wide variety of clinical symptoms and disorders. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subtypes of MGUS</strong> – There are three distinct clinical types of MGUS, each with a risk of progressing through a unique intermediate (more advanced) premalignant stage and then to a malignant plasma cell dyscrasia or lymphoproliferative disorder (see  <a class="medical medical_review" href="/z/d/html/15772.html" rel="external">"Clinical course and management of monoclonal gammopathy of undetermined significance", section on 'Disease progression'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Non-IgM MGUS (IgG, IgA, or IgD MGUS) is the most common type of MGUS and has the potential to progress to smoldering (asymptomatic) multiple myeloma and to symptomatic multiple myeloma. Less frequently, these individuals progress to AL amyloidosis, light chain deposition disease, or another lymphoproliferative disorder.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>IgM MGUS accounts for approximately 15 percent of MGUS cases. It is considered separately from the non-IgM MGUS because it has the potential to progress to smoldering or active Waldenström macroglobulinemia. Infrequently, IgM MGUS can progress to IgM multiple myeloma or AL amyloidosis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Light chain MGUS may progress to idiopathic Bence Jones proteinuria and to light chain multiple myeloma, AL amyloidosis, or light chain deposition disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>When to suspect MGUS</strong> – The presence of MGUS is suspected in an asymptomatic individual in whom a serum monoclonal immunoglobulin has been detected in a concentration of &lt;3 g/dL (30 g/L). (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial evaluation of suspected cases</strong> – At a minimum, individuals suspected of having MGUS should be evaluated with the following studies  (<a class="graphic graphic_algorithm graphicRef94388" href="/z/d/graphic/94388.html" rel="external">algorithm 1</a>) (see <a class="local">'Initial testing for all'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Complete blood count</p><p class="bulletIndent2"><span class="glyph">•</span>Serum calcium and creatinine</p><p class="bulletIndent2"><span class="glyph">•</span>Serum protein electrophoresis (SPEP) and immunofixation</p><p class="bulletIndent2"><span class="glyph">•</span>Serum free light chain (FLC) assay</p><p class="bulletIndent2"><span class="glyph">•</span>Quantitation of immunoglobulins</p><p></p><p class="bulletIndent1">The serum FLC assay can be used initially in place of urine studies. However, if a monoclonal (M) protein is seen on serum studies or if the serum FLC ratio is abnormal, urine electrophoresis and immunofixation need to be performed. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imaging and bone marrow evaluation</strong> – Cross sectional imaging (eg, whole body low dose computed tomography without contrast) and bone marrow aspiration and biopsy are indicated for many individuals with a monoclonal protein  (<a class="graphic graphic_algorithm graphicRef94388" href="/z/d/graphic/94388.html" rel="external">algorithm 1</a>). (See <a class="local">'Cross sectional imaging'</a> above.)</p><p></p><p class="bulletIndent1">Imaging may be omitted based on the discretion of the treating physician in individuals without anemia, hypercalcemia, and kidney impairment and any of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>IgG monoclonal protein &lt;1.5 g/dL (15 g/L) and a normal serum FLC ratio</p><p class="bulletIndent2"><span class="glyph">•</span>Light chain only monoclonal protein with serum FLC ratio &lt;8</p><p class="bulletIndent2"><span class="glyph">•</span>IgM monoclonal protein with no clinical concern for bone lesions or myeloma </p><p></p><p class="bulletIndent1">Bone marrow evaluation may be omitted based on the discretion of the treating physician in individuals with no evidence of anemia, hypercalcemia, kidney impairment, lymphadenopathy, or organomegaly and any of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>IgG monoclonal protein &lt;1.5 g/dL (15 g/L) with normal FLC ratio</p><p class="bulletIndent2"><span class="glyph">•</span>Light chain only monoclonal protein with FLC ratio &lt;8</p><p class="bulletIndent2"><span class="glyph">•</span>IgM monoclonal protein &lt;1.5 g/dL (15 g/L)  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic criteria</strong> – The diagnosis of MGUS (non-IgM and IgM) is confirmed when the following criteria have been met  (<a class="graphic graphic_table graphicRef57627" href="/z/d/graphic/57627.html" rel="external">table 5</a>) (see <a class="local">'Diagnostic criteria'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The presence of a serum M protein (whether IgA, IgG, or IgM), at a concentration &lt;3 g/dL (30 g/L) detected with SPEP and immunofixation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Involved/uninvolved FLC ratio &lt;100.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fewer than 10 percent plasma cells in the bone marrow (if indicated). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The absence of lytic bone lesions, anemia, hypercalcemia, and kidney impairment or other myeloma-defining events related to the plasma cell proliferative process.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Individuals should not have leukocytosis, abnormal circulating cells, lymphadenopathy, hepatomegaly, splenomegaly, or undiagnosed mass lesions that can be attributed to a clonal plasma cell or lymphoproliferative disorder.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – MGUS must be differentiated from diseases that also present with a monoclonal gammopathy. These include multiple myeloma (smoldering or symptomatic), Waldenström macroglobulinemia (smoldering or symptomatic), light chain smoldering multiple myeloma (idiopathic Bence Jones proteinuria), and primary amyloidosis (AL)  (<a class="graphic graphic_table graphicRef130091" href="/z/d/graphic/130091.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef67431" href="/z/d/graphic/67431.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef57627" href="/z/d/graphic/57627.html" rel="external">table 5</a>). (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="headingAnchor" id="H2524355980"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate would like to acknowledge Robert A Kyle, MD, who made extensive contributions to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15:e538.</a></li><li><a class="nounderline abstract_t">Kyle RA, Larson DR, Therneau TM, et al. Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study. Lancet Haematol 2014; 1:e28.</a></li><li><a class="nounderline abstract_t">Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance. Br J Haematol 2006; 134:573.</a></li><li><a class="nounderline abstract_t">Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression. Br J Haematol 2007; 139:730.</a></li><li><a class="nounderline abstract_t">Bird J, Behrens J, Westin J, et al. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 2009; 147:22.</a></li><li><a class="nounderline abstract_t">Kyle RA, Durie BG, Rajkumar SV, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010; 24:1121.</a></li><li><a class="nounderline abstract_t">Axelsson U. A 20-year follow-up study of 64 subjects with M-components. Acta Med Scand 1986; 219:519.</a></li><li><a class="nounderline abstract_t">Kyle RA, Finkelstein S, Elveback LR, Kurland LT. Incidence of monoclonal proteins in a Minnesota community with a cluster of multiple myeloma. Blood 1972; 40:719.</a></li><li><a class="nounderline abstract_t">Saleun JP, Vicariot M, Deroff P, Morin JF. Monoclonal gammopathies in the adult population of Finistère, France. J Clin Pathol 1982; 35:63.</a></li><li><a class="nounderline abstract_t">Neriishi K, Nakashima E, Suzuki G. Monoclonal gammopathy of undetermined significance in atomic bomb survivors: incidence and transformation to multiple myeloma. Br J Haematol 2003; 121:405.</a></li><li><a class="nounderline abstract_t">Iwanaga M, Tagawa M, Tsukasaki K, et al. Prevalence of monoclonal gammopathy of undetermined significance: study of 52,802 persons in Nagasaki City, Japan. Mayo Clin Proc 2007; 82:1474.</a></li><li><a class="nounderline abstract_t">Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006; 354:1362.</a></li><li><a class="nounderline abstract_t">Smith A, Howell D, Patmore R, et al. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer 2011; 105:1684.</a></li><li><a class="nounderline abstract_t">Crawford J, Eye MK, Cohen HJ. Evaluation of monoclonal gammopathies in the "well" elderly. Am J Med 1987; 82:39.</a></li><li><a class="nounderline abstract_t">Therneau TM, Kyle RA, Melton LJ 3rd, et al. Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition. Mayo Clin Proc 2012; 87:1071.</a></li><li><a class="nounderline abstract_t">Singh J, Dudley AW Jr, Kulig KA. Increased incidence of monoclonal gammopathy of undetermined significance in blacks and its age-related differences with whites on the basis of a study of 397 men and one woman in a hospital setting. J Lab Clin Med 1990; 116:785.</a></li><li><a class="nounderline abstract_t">Cohen HJ, Crawford J, Rao MK, et al. Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly. Am J Med 1998; 104:439.</a></li><li><a class="nounderline abstract_t">Landgren O, Gridley G, Turesson I, et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood 2006; 107:904.</a></li><li><a class="nounderline abstract_t">Landgren O, Katzmann JA, Hsing AW, et al. Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc 2007; 82:1468.</a></li><li><a class="nounderline abstract_t">Wadhera RK, Rajkumar SV. Prevalence of monoclonal gammopathy of undetermined significance: a systematic review. Mayo Clin Proc 2010; 85:933.</a></li><li><a class="nounderline abstract_t">Murray D, Kumar SK, Kyle RA, et al. Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement. Blood Cancer J 2019; 9:102.</a></li><li><a class="nounderline abstract_t">El-Khoury H, Lee DJ, Alberge JB, et al. Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study. Lancet Haematol 2022; 9:e340.</a></li><li><a class="nounderline abstract_t">Dispenzieri A, Katzmann JA, Kyle RA, et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet 2010; 375:1721.</a></li><li><a class="nounderline abstract_t">Landgren O, Rajkumar SV, Pfeiffer RM, et al. Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women. Blood 2010; 116:1056.</a></li><li><a class="nounderline abstract_t">Ruiz-Delgado GJ, Gómez Rangel JD. [Monoclonal gammopathy of undetermined significance (MGUS) in Mexican mestizos: one institution's experience]. Gac Med Mex 2004; 140:375.</a></li><li><a class="nounderline abstract_t">Greenberg AJ, Rajkumar SV, Vachon CM. Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics. Blood 2012; 119:5359.</a></li><li><a class="nounderline abstract_t">Landgren O, Kristinsson SY, Goldin LR, et al. Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. Blood 2009; 114:791.</a></li><li><a class="nounderline abstract_t">Vachon CM, Kyle RA, Therneau TM, et al. Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. Blood 2009; 114:785.</a></li><li><a class="nounderline abstract_t">Greenberg AJ, Rajkumar SV, Larson DR, et al. Increased prevalence of light chain monoclonal gammopathy of undetermined significance (LC-MGUS) in first-degree relatives of individuals with multiple myeloma. Br J Haematol 2012; 157:472.</a></li><li><a class="nounderline abstract_t">Clay-Gilmour AI, Kumar S, Rajkumar SV, et al. Risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristics. Leukemia 2019; 33:499.</a></li><li><a class="nounderline abstract_t">Broderick P, Chubb D, Johnson DC, et al. Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk. Nat Genet 2011; 44:58.</a></li><li><a class="nounderline abstract_t">Chubb D, Weinhold N, Broderick P, et al. Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk. Nat Genet 2013; 45:1221.</a></li><li><a class="nounderline abstract_t">Weinhold N, Johnson DC, Rawstron AC, et al. Inherited genetic susceptibility to monoclonal gammopathy of unknown significance. Blood 2014; 123:2513.</a></li><li><a class="nounderline abstract_t">Vanderschueren S, Mylle M, Dierickx D, et al. Monoclonal gammopathy of undetermined significance: significant beyond hematology. Mayo Clin Proc 2009; 84:842.</a></li><li><a class="nounderline abstract_t">Rossi D, De Paoli L, Franceschetti S, et al. Prevalence and clinical characteristics of immune thrombocytopenic purpura in a cohort of monoclonal gammopathy of uncertain significance. Br J Haematol 2007; 138:249.</a></li><li><a class="nounderline abstract_t">Lindqvist EK, Goldin LR, Landgren O, et al. Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study. Blood 2011; 118:6284.</a></li><li><a class="nounderline abstract_t">Bida JP, Kyle RA, Therneau TM, et al. Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients. Mayo Clin Proc 2009; 84:685.</a></li><li><a class="nounderline abstract_t">Melton LJ 3rd, Rajkumar SV, Khosla S, et al. Fracture risk in monoclonal gammopathy of undetermined significance. J Bone Miner Res 2004; 19:25.</a></li><li><a class="nounderline abstract_t">Bazari H, Attar EC, Dahl DM, et al. Case records of the Massachusetts General Hospital. Case 23-2010. A 49-year-old man with erythrocytosis, perinephric fluid collections, and renal failure. N Engl J Med 2010; 363:463.</a></li><li><a class="nounderline abstract_t">Sykes DB, Schroyens W, O'Connell C. The TEMPI syndrome--a novel multisystem disease. N Engl J Med 2011; 365:475.</a></li><li><a class="nounderline abstract_t">Kwok M, Korde N, Landgren O. Bortezomib to treat the TEMPI syndrome. N Engl J Med 2012; 366:1843.</a></li><li><a class="nounderline abstract_t">Sykes DB, O'Connell C, Schroyens W. The TEMPI syndrome. Blood 2020; 135:1199.</a></li><li><a class="nounderline abstract_t">Schroyens W, O'Connell C, Sykes DB. Complete and partial responses of the TEMPI syndrome to bortezomib. N Engl J Med 2012; 367:778.</a></li><li><a class="nounderline abstract_t">Kenderian SS, Rosado FG, Sykes DB, et al. Long-term complete clinical and hematological responses of the TEMPI syndrome after autologous stem cell transplantation. Leukemia 2015; 29:2414.</a></li><li><a class="nounderline abstract_t">Sykes DB, Schroyens W. Complete Responses in the TEMPI Syndrome after Treatment with Daratumumab. N Engl J Med 2018; 378:2240.</a></li><li><a class="nounderline abstract_t">Kyle RA, Larson DR, Therneau TM, et al. Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance. N Engl J Med 2018; 378:241.</a></li><li><a class="nounderline abstract_t">Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346:564.</a></li><li><a class="nounderline abstract_t">Blade J, Lopez-Guillermo A, Rozman C, et al. Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance. Br J Haematol 1992; 81:391.</a></li><li><a class="nounderline abstract_t">Kyle RA. "Benign" monoclonal gammopathy--after 20 to 35 years of follow-up. Mayo Clin Proc 1993; 68:26.</a></li><li><a class="nounderline abstract_t">Kyle RA, Robinson RA, Katzmann JA. The clinical aspects of biclonal gammopathies. Review of 57 cases. Am J Med 1981; 71:999.</a></li><li><a class="nounderline abstract_t">Kumar S, Rajkumar SV, Kyle RA, et al. Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. J Clin Oncol 2005; 23:5668.</a></li><li><a class="nounderline abstract_t">Witzig TE, Kyle RA, O'Fallon WM, Greipp PR. Detection of peripheral blood plasma cells as a predictor of disease course in patients with smouldering multiple myeloma. Br J Haematol 1994; 87:266.</a></li><li><a class="nounderline abstract_t">Fonseca R, Bailey RJ, Ahmann GJ, et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 2002; 100:1417.</a></li><li><a class="nounderline abstract_t">Zandecki M, Laï JL, Geneviève F, et al. Several cytogenetic subclones may be identified within plasma cells from patients with monoclonal gammopathy of undetermined significance, both at diagnosis and during the indolent course of this condition. Blood 1997; 90:3682.</a></li><li><a class="nounderline abstract_t">Rasillo A, Tabernero MD, Sánchez ML, et al. Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia. Cancer 2003; 97:601.</a></li><li><a class="nounderline abstract_t">Brousseau M, Leleu X, Gerard J, et al. Hyperdiploidy is a common finding in monoclonal gammopathy of undetermined significance and monosomy 13 is restricted to these hyperdiploid patients. Clin Cancer Res 2007; 13:6026.</a></li><li><a class="nounderline abstract_t">Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002; 2:175.</a></li><li><a class="nounderline abstract_t">Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 351:1860.</a></li><li><a class="nounderline abstract_t">Chang H, Yeung J, Xu W, et al. Significant increase of CKS1B amplification from monoclonal gammopathy of undetermined significance to multiple myeloma and plasma cell leukaemia as demonstrated by interphase fluorescence in situ hybridisation. Br J Haematol 2006; 134:613.</a></li><li><a class="nounderline abstract_t">Berenson JR, Anderson KC, Audell RA, et al. Monoclonal gammopathy of undetermined significance: a consensus statement. Br J Haematol 2010; 150:28.</a></li><li><a class="nounderline abstract_t">Go RS, Rajkumar SV. How I manage monoclonal gammopathy of undetermined significance. Blood 2018; 131:163.</a></li><li><a class="nounderline abstract_t">Rajan AM, Rajkumar SV. Diagnostic evaluation of monoclonal gammopathy of undetermined significance. Eur J Haematol 2013; 91:561.</a></li><li><a class="nounderline abstract_t">Mangiacavalli S, Cocito F, Pochintesta L, et al. Monoclonal gammopathy of undetermined significance: a new proposal of workup. Eur J Haematol 2013; 91:356.</a></li><li><a class="nounderline abstract_t">Hillengass J, Usmani S, Rajkumar SV, et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol 2019; 20:e302.</a></li><li><a class="nounderline abstract_t">Eythorsson E, Rognvaldsson S, Thorsteinsdottir S, et al. Predicting the Need for Upfront Bone Marrow Sampling in Individuals with MGUS: Derivation of a Multivariable Prediction Model Using the Prospective Population-Based Istopmm Cohort (abstract 107). Blood 2019.</a></li><li><a class="nounderline abstract_t">Kyle RA. Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. Am J Med 1978; 64:814.</a></li><li><a class="nounderline abstract_t">International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121:749.</a></li><li><a class="nounderline abstract_t">Kyle RA. The monoclonal gammopathies. Clin Chem 1994; 40:2154.</a></li><li><a class="nounderline abstract_t">Kyle RA, Therneau TM, Rajkumar SV, et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood 2003; 102:3759.</a></li><li><a class="nounderline abstract_t">Long TE, Indridason OS, Palsson R, et al. Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study. Blood Cancer J 2022; 12:133.</a></li><li><a class="nounderline abstract_t">Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002; 48:1437.</a></li><li><a class="nounderline abstract_t">Millá F, Oriol A, Aguilar J, et al. Usefulness and reproducibility of cytomorphologic evaluations to differentiate myeloma from monoclonal gammopathies of unknown significance. Am J Clin Pathol 2001; 115:127.</a></li><li><a class="nounderline abstract_t">Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78:21.</a></li><li><a class="nounderline abstract_t">Leung N, Bridoux F, Hutchison CA, et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood 2012; 120:4292.</a></li><li><a class="nounderline abstract_t">Bataille R, Jourdan M, Zhang XG, Klein B. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 1989; 84:2008.</a></li><li><a class="nounderline abstract_t">Gonchoroff NJ, Greipp PR, Kyle RA, Katzmann JA. A monoclonal antibody reactive with 5-bromo-2-deoxyuridine that does not require DNA denaturation. Cytometry 1985; 6:506.</a></li><li><a class="nounderline abstract_t">Roodman GD. Role of the bone marrow microenvironment in multiple myeloma. J Bone Miner Res 2002; 17:1921.</a></li><li><a class="nounderline abstract_t">Abe M, Hiura K, Wilde J, et al. Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood 2002; 100:2195.</a></li><li><a class="nounderline abstract_t">Lacy MQ, Donovan KA, Heimbach JK, et al. Comparison of interleukin-1 beta expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 1999; 93:300.</a></li><li><a class="nounderline abstract_t">Kyle RA, Greipp PR. Smoldering multiple myeloma. N Engl J Med 1980; 302:1347.</a></li><li><a class="nounderline abstract_t">Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007; 356:2582.</a></li><li><a class="nounderline abstract_t">Rajkumar SV, Larson D, Kyle RA. Diagnosis of smoldering multiple myeloma. N Engl J Med 2011; 365:474.</a></li><li><a class="nounderline abstract_t">Kyle RA, Greipp PR. "Idiopathic" Bence Jones proteinuria: long-term follow-up in seven patients. N Engl J Med 1982; 306:564.</a></li><li><a class="nounderline abstract_t">Wadhera RK, Kyle RA, Larson DR, et al. Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma. Blood 2011; 118:2985.</a></li><li><a class="nounderline abstract_t">Leleu X, Moreau AS, Weller E, et al. Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia. Leuk Lymphoma 2008; 49:1104.</a></li><li><a class="nounderline abstract_t">Landgren O, Staudt L. MYD88 L265P somatic mutation in IgM MGUS. N Engl J Med 2012; 367:2255.</a></li><li><a class="nounderline abstract_t">Xu L, Hunter ZR, Yang G, et al. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood 2013; 121:2051.</a></li><li><a class="nounderline abstract_t">Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003; 30:110.</a></li></ol></div><div id="topicVersionRevision">Topic 6652 Version 63.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25439696" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25530988" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16938117" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Monoclonal gammopathy of undetermined significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18021088" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19673884" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20410922" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3739756" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A 20-year follow-up study of 64 subjects with M-components.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4627911" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Incidence of monoclonal proteins in a Minnesota community with a cluster of multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6801095" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Monoclonal gammopathies in the adult population of Finistère, France.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12716362" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Monoclonal gammopathy of undetermined significance in atomic bomb survivors: incidence and transformation to multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18053454" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Prevalence of monoclonal gammopathy of undetermined significance: study of 52,802 persons in Nagasaki City, Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16571879" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Prevalence of monoclonal gammopathy of undetermined significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22045184" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3492143" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Evaluation of monoclonal gammopathies in the "well" elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22883742" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2246554" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Increased incidence of monoclonal gammopathy of undetermined significance in blacks and its age-related differences with whites on the basis of a study of 397 men and one woman in a hospital setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9626026" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16210333" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18053453" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20713974" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Prevalence of monoclonal gammopathy of undetermined significance: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31836698" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35344689" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20472173" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20421448" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15456147" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : [Monoclonal gammopathy of undetermined significance (MGUS) in Mexican mestizos: one institution's experience].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22354002" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19182202" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19179466" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22629552" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Increased prevalence of light chain monoclonal gammopathy of undetermined significance (LC-MGUS) in first-degree relatives of individuals with multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30201985" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22120009" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23955597" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24449210" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Inherited genetic susceptibility to monoclonal gammopathy of unknown significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19720783" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Monoclonal gammopathy of undetermined significance: significant beyond hematology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17535272" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Prevalence and clinical characteristics of immune thrombocytopenic purpura in a cohort of monoclonal gammopathy of uncertain significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21998210" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19648385" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14753733" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Fracture risk in monoclonal gammopathy of undetermined significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20818867" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Case records of the Massachusetts General Hospital. Case 23-2010. A 49-year-old man with erythrocytosis, perinephric fluid collections, and renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21812700" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The TEMPI syndrome--a novel multisystem disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22571216" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Bortezomib to treat the TEMPI syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32108223" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The TEMPI syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22913703" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Complete and partial responses of the TEMPI syndrome to bortezomib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26500143" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Long-term complete clinical and hematological responses of the TEMPI syndrome after autologous stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29874534" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Complete Responses in the TEMPI Syndrome after Treatment with Daratumumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29342381" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11856795" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : A long-term study of prognosis in monoclonal gammopathy of undetermined significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1390212" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8417251" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : "Benign" monoclonal gammopathy--after 20 to 35 years of follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6797297" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The clinical aspects of biclonal gammopathies. Review of 57 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16110026" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7947266" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Detection of peripheral blood plasma cells as a predictor of disease course in patients with smouldering multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12149226" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Genomic abnormalities in monoclonal gammopathy of undetermined significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9345053" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Several cytogenetic subclones may be identified within plasma cells from patients with monoclonal gammopathy of undetermined significance, both at diagnosis and during the indolent course of this condition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12548602" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17947464" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Hyperdiploidy is a common finding in monoclonal gammopathy of undetermined significance and monosomy 13 is restricted to these hyperdiploid patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11990854" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Multiple myeloma: evolving genetic events and host interactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15509819" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16889615" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Significant increase of CKS1B amplification from monoclonal gammopathy of undetermined significance to multiple myeloma and plasma cell leukaemia as demonstrated by interphase fluorescence in situ hybridisation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20507313" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Monoclonal gammopathy of undetermined significance: a consensus statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29183887" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : How I manage monoclonal gammopathy of undetermined significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24033731" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Diagnostic evaluation of monoclonal gammopathy of undetermined significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23859528" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Monoclonal gammopathy of undetermined significance: a new proposal of workup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31162104" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Predicting the Need for Upfront Bone Marrow Sampling in Individuals with MGUS: Derivation of a Multivariable Prediction Model Using the Prospective Population-Based Istopmm Cohort (abstract 107)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/645746" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Monoclonal gammopathy of undetermined significance. Natural history in 241 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12780789" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7955402" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The monoclonal gammopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12881316" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Long-term follow-up of IgM monoclonal gammopathy of undetermined significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36100605" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12194920" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11190798" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Usefulness and reproducibility of cytomorphologic evaluations to differentiate myeloma from monoclonal gammopathies of unknown significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12528874" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Review of 1027 patients with newly diagnosed multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23047823" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2592570" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3905299" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : A monoclonal antibody reactive with 5-bromo-2-deoxyuridine that does not require DNA denaturation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12412796" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Role of the bone marrow microenvironment in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12200385" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9864174" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Comparison of interleukin-1 beta expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7374679" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Smoldering multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17582068" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21812699" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Diagnosis of smoldering multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7057813" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : "Idiopathic" Bence Jones proteinuria: long-term follow-up in seven patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21765020" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18452095" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23215570" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : MYD88 L265P somatic mutation in IgM MGUS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23321251" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12720118" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
